For the Media

SYNTAX Trial
Resources and Media Information
Updated: October 22, 2008

• PRESS RELEASE - September 2, 2008: SYNTAX Trial Affirms Bypass Surgery Superiority in Treatment of Complex Coronary Disease
• Drug-Eluting Stents - Pushing the Envelope Beyond the Labels?, by Joseph P. Carrozza, Jr., MD, New England Journal of Medicine, January 2008.
• Drug-Eluting Stents vs. Coronary Artery Bypass Grafting in Multivessel Coronary Disease, by E.L. Hannan, PhD, et al, New England Journal of Medicine, January 2008.
• Lower Mortality With Coronary Bypass Compared to Drug-Eluting Stents for Multi-Vessel Disease Patients, by Robert A. Guyton, MD, New England Journal of Medicine, February 2008. *Important points from NEJM report.
• Coronary Artery Bypass is Superior to Drug-Eluting Stents in Multi-Vessel Coronary Artery Disease, by Robert A. Guyton, MD, The Annals of Thoracic Surgery 2006;81:1949-57.
• Coronary Artery Bypass IS the Best Treatment for Multi-Vessel Coronary Disease in 2007, presentation by Robert A. Guyton, MD.
• Surgical Perspective on Coronary Revascularization 2008, presentation by Robert A. Guyton, MD.
• Coronary Artery Bypass Grafting is Still the Best Treatment for Multi-Vessel and Left Main Disease - But Patients Need to Know, by David P. Taggart, MD, PhD, The Annals of Thoracic Surgery 2006;82:1966-75.
• In the News: CABG Procedures to Rise in 2007
• In the News: Doctors Rethink Widespread Use of Heart Stents 
• About The Society of Thoracic Surgeons (STS)
• Who are Cardiothoracic (CT) Surgeons?

------------------------------------------------------------------------

Heart and Lung Surgeon Shortage Imminent:
Health Care Reform Must Address Access to Care
June 2008 -- Media Kit